BPDCN: When Polychemotherapy Does Not Compromise Allogeneic CD123 CAR-T Cell Cytotoxicity

Overview

Journal EJHaem

Specialty Hematology

Date 2022 Jul 18

PMID 35846081

Authors

Margaux Poussard

Laure Philippe

Maxime Fredon

Elodie Bole-Richard

Sabeha Biichle

Florian Renosi

Sophie Perrin

Marie Kroemer

Samuel Limat

Francis Bonnefoy

Etienne Daguindau

Eric Deconinck

Berengere Gruson

Philippe Saas

Olivier Adotevi

Francine Garnache-Ottou

Fanny Angelot-Delettre

Affiliations

Soon will be listed here.

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these therapies, the influence of one on the other has to be explored. We set up a model to test the combination of polychemotherapy - named methotrexate, idarubicine, dexamethasone, and L-asparaginase (MIDA) - and CD123 CAR-T cell therapy. We showed that CD123 CAR-T cells exert the same effect on BPDCN models alone, or after MIDA regimen. These data support a preclinical rationale to use immunotherapy after a treatment with polychemotherapy for BPDCN patients.

Citing Articles

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicity.

Poussard M, Philippe L, Fredon M, Bole-Richard E, Biichle S, Renosi F EJHaem. 2022; 2(1):125-130.

PMID: 35846081 PMC: 9176134. DOI: 10.1002/jha2.149.

References

Angelot-Delettre F, Roggy A, Frankel A, Lamarthee B, Seilles E, Biichle S . In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica. 2014; 100(2):223-30. PMC: 4803130. DOI: 10.3324/haematol.2014.111740. View

Bole-Richard E, Fredon M, Biichle S, Anna F, Certoux J, Renosi F . CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia. 2020; 34(12):3228-3241. DOI: 10.1038/s41375-020-0777-1. View

Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R . Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014; 10(11):1519-30. DOI: 10.1586/1744666X.2014.962996. View

Gruson B, Vaida I, Merlusca L, Charbonnier A, Parcelier A, Damaj G . L-asparaginase with methotrexate and dexamethasone is an effective treatment combination in blastic plasmacytoid dendritic cell neoplasm. Br J Haematol. 2013; 163(4):543-5. DOI: 10.1111/bjh.12523. View

Poussard M, Philippe L, Fredon M, Bole-Richard E, Biichle S, Renosi F . BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicity. EJHaem. 2022; 2(1):125-130. PMC: 9176134. DOI: 10.1002/jha2.149. View

Hay K, Hanafi L, Li D, Gust J, Liles W, Wurfel M . Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017; 130(21):2295-2306. PMC: 5701525. DOI: 10.1182/blood-2017-06-793141. View

Watanabe K, Terakura S, Martens A, van Meerten T, Uchiyama S, Imai M . Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells. J Immunol. 2014; 194(3):911-20. DOI: 10.4049/jimmunol.1402346. View

Dietrich S, Andrulis M, Hegenbart U, Schmitt T, Bellos F, Martens U . Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant. 2011; 17(8):1250-4. DOI: 10.1016/j.bbmt.2010.12.706. View

Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E . Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood. 2012; 121(3):440-6. DOI: 10.1182/blood-2012-08-448613. View

10.

Garnache-Ottou F, Vidal C, Biichle S, Renosi F, Poret E, Pagadoy M . How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. Blood Adv. 2019; 3(24):4238-4251. PMC: 6929390. DOI: 10.1182/bloodadvances.2019000647. View

11.

Fontaine J, Thomas L, Balme B, Ronger-Savle S, Traulle C, Petrella T . Haematodermic CD4+CD56+ neoplasm: complete remission after methotrexate-asparaginase treatment. Clin Exp Dermatol. 2009; 34(5):e43-5. DOI: 10.1111/j.1365-2230.2008.03100.x. View

12.

Testa U, Pelosi E, Castelli G . CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers (Basel). 2019; 11(9). PMC: 6769702. DOI: 10.3390/cancers11091358. View

13.

Giles A, Hutchinson M, Sonnemann H, Jung J, Fecci P, Ratnam N . Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018; 6(1):51. PMC: 5996496. DOI: 10.1186/s40425-018-0371-5. View

14.

Pagano L, Valentini C, Pulsoni A, Fisogni S, Carluccio P, Mannelli F . Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2012; 98(2):239-46. PMC: 3561431. DOI: 10.3324/haematol.2012.072645. View

15.

Garnache-Ottou F, Feuillard J, Ferrand C, Biichle S, Trimoreau F, Seilles E . Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009; 145(5):624-36. DOI: 10.1111/j.1365-2141.2009.07679.x. View

16.

Gilis L, Lebras L, Bouafia-Sauvy F, Espinouse D, Felman P, Berger F . Sequential combination of high dose methotrexate and L-asparaginase followed by allogeneic transplant: a first-line strategy for CD4+/CD56+ hematodermic neoplasm. Leuk Lymphoma. 2012; 53(8):1633-7. DOI: 10.3109/10428194.2012.656627. View